Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 37,700 shares, an increase of 158.2% from the November 15th total of 14,600 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average trading volume of 137,400 shares, the days-to-cover ratio is currently 0.3 days.

Estrella Immunopharma Stock Performance

NASDAQ:ESLA traded up $0.01 during midday trading on Wednesday, reaching $1.38. 163,829 shares of the stock traded hands, compared to its average volume of 76,462. The stock has a market capitalization of $49.93 million, a PE ratio of -5.31 and a beta of 0.46. Estrella Immunopharma has a 12-month low of $0.63 and a 12-month high of $3.23. The business has a 50-day moving average of $0.95 and a two-hundred day moving average of $1.10.

Estrella Immunopharma (NASDAQ:ESLA) last announced its earnings results on Friday, September 27th. The company reported ($0.13) earnings per share for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.